Sean Koppe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sean Koppe has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Daniel K Martin
Department of Gastroenterology and Hepatology, University of Illinois College of Medicine, Peoria, IL, USA
2 shared publicationsHarsha Moole
Department of Internal Medicine, University of Illinois College of Medicine, Peoria, IL, USA
2 shared publications- Jinma Ren
Department of Center for Outcomes Research, University of Illinois College of Medicine, Peoria, IL, USA
2 shared publications Ruben Khan
Department of Gastroenterology and Hepatology University of Illinois at Chicago Chicago IL
2 shared publicationsSaqib Walayat
Department of Internal Medicine, University of Illinois College of Medicine, Peoria, IL, USA
2 shared publications- Sarang Thaker
Department of Medicine, Division of Gastroenterology and Hepatology, University of Illinois at Chicago, Chicago, IL
2 shared publications
Latest Publications
- 1 March 2023
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 21 (3) , 73-75
CON: Is liver organ allocation with MMaT-3 appropriate prioritization for patients with liver cancer?
- 1 March 2023
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 21 (3) , 73-75
CON: Is liver organ allocation with MMaT-3 appropriate prioritization for patients with liver cancer?
- Open Access
- 10 November 2022
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 8 (12) , e1405
Hilar Biliary Amputation Neuroma Following Liver Transplant: A Case Report and Review of the Literature for this Diagnostic and Therapeutic Challenge
- 10 November 2022
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 8 (12) , e1405
Open AccessHilar Biliary Amputation Neuroma Following Liver Transplant: A Case Report and Review of the Literature for this Diagnostic and Therapeutic Challenge
- 5 February 2022
- Published by Wolters Kluwer Health in Hepatology
- Vol. 75 (4) , 777-778
Measure twice, cut once
- 5 February 2022
- Published by Wolters Kluwer Health in Hepatology
- Vol. 75 (4) , 777-778
Measure twice, cut once
- Open Access
- 22 September 2021
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2021 (9) , rjab418
Colonic leiomyoma mimicking a liver tumor: an unusual diagnosis after en-block robotic resection
Colonic leiomyomas are rare. Their clinical presentation ranges from asymptomatic polyps detected on endoscopy to large symptomatic abdominopelvic masses. Imaging findings are usually non-specific, and percutaneous biopsy might help with differential diagnosis. However, radical surgery with negative margins is ultimately needed to rule out malignancy. We describe an uncommon presentation of a colonic leiomyoma mimicking a right hepatic lobe tumor on preoperative imaging. The robotic approach allowed a precise abdominal exploration with confirmation of colonic and hepatic infiltration and subsequent oncological en-block resection. Surgeons operating on hepatic tumors close to the right colic flexure should be aware of this diagnosis.
- 22 September 2021
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2021 (9) , rjab418
Open AccessColonic leiomyoma mimicking a liver tumor: an unusual diagnosis after en-block robotic resection
Colonic leiomyomas are rare. Their clinical presentation ranges from asymptomatic polyps detected on endoscopy to large symptomatic abdominopelvic masses. Imaging findings are usually non-specific, and percutaneous biopsy might help with differential diagnosis. However, radical surgery with negative margins is ultimately needed to rule out malignancy. We describe an uncommon presentation of a colonic leiomyoma mimicking a right hepatic lobe tumor on preoperative imaging. The robotic approach allowed a precise abdominal exploration with confirmation of colonic and hepatic infiltration and subsequent oncological en-block resection. Surgeons operating on hepatic tumors close to the right colic flexure should be aware of this diagnosis.
- 21 November 2019
- Published by Georg Thieme Verlag KG in Digestive Disease Interventions
- Vol. 03 (04) , 255-262
Pre-Liver Transplantation Evaluation and Listing
Liver transplantation provides a curative treatment option for patients with both acute and chronic liver disease, but the decision to list a patient for transplant should be an informed one to maximize post-transplantation benefit and survivability. Potential candidates meeting transplantation indications must undergo a comprehensive evaluation consisting of both physical, as well as psychiatric, assessment to be considered for transplantation. Once listed, a candidate's place on the liver transplant waiting list is determined predominantly by his or her Model for End-Stage Liver Disease (MELD)-Na score, which is a reliable tool to stratify short-term survival risk. The severity of certain conditions, however, is not accurately reflected by the MELD-Na score, and these particular diagnoses may be assigned MELD exception points. Herein, we discuss common indications for liver transplantation: the MELD system and its exceptions, the physical and psychosocial evaluation of potential transplant candidates, and some limitations of the current organ allocation system and efforts to reduce disparity in organ distribution.
- 21 November 2019
- Published by Georg Thieme Verlag KG in Digestive Disease Interventions
- Vol. 03 (04) , 255-262
Pre-Liver Transplantation Evaluation and Listing
Liver transplantation provides a curative treatment option for patients with both acute and chronic liver disease, but the decision to list a patient for transplant should be an informed one to maximize post-transplantation benefit and survivability. Potential candidates meeting transplantation indications must undergo a comprehensive evaluation consisting of both physical, as well as psychiatric, assessment to be considered for transplantation. Once listed, a candidate's place on the liver transplant waiting list is determined predominantly by his or her Model for End-Stage Liver Disease (MELD)-Na score, which is a reliable tool to stratify short-term survival risk. The severity of certain conditions, however, is not accurately reflected by the MELD-Na score, and these particular diagnoses may be assigned MELD exception points. Herein, we discuss common indications for liver transplantation: the MELD system and its exceptions, the physical and psychosocial evaluation of potential transplant candidates, and some limitations of the current organ allocation system and efforts to reduce disparity in organ distribution.
- Open Access
- 1 November 2018
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 12 (5) , 137-139
All Patients With Advanced Fibrosis Should Continue to Be Screened for Hepatocellular Carcinoma After Sustained Virological Response of Hepatitis C Virus
- 1 November 2018
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 12 (5) , 137-139
Open AccessAll Patients With Advanced Fibrosis Should Continue to Be Screened for Hepatocellular Carcinoma After Sustained Virological Response of Hepatitis C Virus
- Open Access
- 1 September 2018
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 11, 533-542
Obesity and nonalcoholic fatty liver disease: current perspectives
Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common cause of chronic liver disease due to an increase in the prevalence of obesity. The development of NASH leads to an increase in morbidity and mortality. While the first line of treatment is lifestyle modifications, including dietary changes and increased physical activity, there are no approved pharmacological treatment agents for NAFLD and NASH currently. Due to its complex pathophysiology, different pathways are under investigation for drug development with the focus on metabolic pathways, inflammation, and slowing or reversing fibrosis. There are several agents advancing in clinical trials, and promising results have been seen with drugs that affect hepatic steatosis, inflammation, and fibrosis. This review will provide an overview on NAFLD and some of the mechanisms of disease that are being targeted with pharmacologic agents.
- 1 September 2018
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 11, 533-542
Open AccessObesity and nonalcoholic fatty liver disease: current perspectives
Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common cause of chronic liver disease due to an increase in the prevalence of obesity. The development of NASH leads to an increase in morbidity and mortality. While the first line of treatment is lifestyle modifications, including dietary changes and increased physical activity, there are no approved pharmacological treatment agents for NAFLD and NASH currently. Due to its complex pathophysiology, different pathways are under investigation for drug development with the focus on metabolic pathways, inflammation, and slowing or reversing fibrosis. There are several agents advancing in clinical trials, and promising results have been seen with drugs that affect hepatic steatosis, inflammation, and fibrosis. This review will provide an overview on NAFLD and some of the mechanisms of disease that are being targeted with pharmacologic agents.
- Open Access
- 1 August 2018
- Published by Taylor & Francis in Clinical and Experimental Gastroenterology
- Vol. ume 11, 301-307
Liver function tests in identifying patients with liver disease
Background and aims: Many patients with liver disease come to medical attention once they have advanced cirrhosis or acute decompensation. Most often, patients are screened for liver disease via liver function tests (LFTs). There is very limited published data evaluating laboratory values with biopsy-proven stages of hepatic fibrosis. We set out to evaluate whether any correlation exists between routine LFTs and stages of hepatic fibrosis. Methods: A large retrospective observational study on 771 liver biopsies was conducted for evaluating the stage of fibrosis with AST, ALT, INR, BUN, creatinine, platelets, alkaline phosphatase, bilirubin, and albumin. Mean and 95% confidence intervals were used to describe the distributions of serum markers in different fibrosis stages. Multivariable generalized linear models were used and a two-tailed P-value was calculated. Results: ALT was not statistically significant for any stage, and AST was statistically significant for stage 3 and 4 fibrosis. INR was statistically significant only in stage 4 disease but remained near the upper limit of normal range. Albumin failed to show a clinically relevant association. Platelets remained within normal laboratory range for all stages. The remaining laboratory values failed to show statistical and clinical significance. Conclusion: The health care burden from chronic liver disease (CLD) will likely continue to rise, unless clinicians are made aware that normal or near normal laboratory findings may be seen in asymptomatic patients. Earlier identification of asymptomatic patients will allow for treatment with new promising modalities and decrease morbidity and mortality from CLD. Our study shows that laboratory values correlate poorly with liver disease.
- 1 August 2018
- Published by Taylor & Francis in Clinical and Experimental Gastroenterology
- Vol. ume 11, 301-307
Open AccessLiver function tests in identifying patients with liver disease
Background and aims: Many patients with liver disease come to medical attention once they have advanced cirrhosis or acute decompensation. Most often, patients are screened for liver disease via liver function tests (LFTs). There is very limited published data evaluating laboratory values with biopsy-proven stages of hepatic fibrosis. We set out to evaluate whether any correlation exists between routine LFTs and stages of hepatic fibrosis. Methods: A large retrospective observational study on 771 liver biopsies was conducted for evaluating the stage of fibrosis with AST, ALT, INR, BUN, creatinine, platelets, alkaline phosphatase, bilirubin, and albumin. Mean and 95% confidence intervals were used to describe the distributions of serum markers in different fibrosis stages. Multivariable generalized linear models were used and a two-tailed P-value was calculated. Results: ALT was not statistically significant for any stage, and AST was statistically significant for stage 3 and 4 fibrosis. INR was statistically significant only in stage 4 disease but remained near the upper limit of normal range. Albumin failed to show a clinically relevant association. Platelets remained within normal laboratory range for all stages. The remaining laboratory values failed to show statistical and clinical significance. Conclusion: The health care burden from chronic liver disease (CLD) will likely continue to rise, unless clinicians are made aware that normal or near normal laboratory findings may be seen in asymptomatic patients. Earlier identification of asymptomatic patients will allow for treatment with new promising modalities and decrease morbidity and mortality from CLD. Our study shows that laboratory values correlate poorly with liver disease.
- Open Access
- 11 June 2018
- Published by Springer Nature in Cureus
- Vol. 10 (6) , e2779
Atypical Presentation of Cardiac Tamponade as a Cause of Acute Liver Injury: Case Report and Review of Literature
Pericardial tamponade is a rare cause of acute liver injury due to the compressive effects of an effusion resulting in a poor cardiac output which ultimately leads to ischemia-induced injury. We present a patient with chronic hepatitis C infection and end-stage renal disease who was transferred to our center for further evaluation and management of acute liver injury after presenting to an outside hospital with left upper quadrant abdominal pain, nausea and vomiting. The patient was discovered to have tamponade physiology on transthoracic echocardiogram as an underlying cause of his acute liver injury despite lack of clinical tamponade features. He required pericardiocentesis which eventually led to resolution of the acute liver injury and he was discharged home on day twelve after full recovery. We review the existing literature regarding the epidemiology, pathophysiology, clinical presentation, diagnosis, and treatment of ischemic hepatitis, which is associated with high mortality; therefore early recognition and treatment of the underlying cause are paramount.
- 11 June 2018
- Published by Springer Nature in Cureus
- Vol. 10 (6) , e2779
Open AccessAtypical Presentation of Cardiac Tamponade as a Cause of Acute Liver Injury: Case Report and Review of Literature
Pericardial tamponade is a rare cause of acute liver injury due to the compressive effects of an effusion resulting in a poor cardiac output which ultimately leads to ischemia-induced injury. We present a patient with chronic hepatitis C infection and end-stage renal disease who was transferred to our center for further evaluation and management of acute liver injury after presenting to an outside hospital with left upper quadrant abdominal pain, nausea and vomiting. The patient was discovered to have tamponade physiology on transthoracic echocardiogram as an underlying cause of his acute liver injury despite lack of clinical tamponade features. He required pericardiocentesis which eventually led to resolution of the acute liver injury and he was discharged home on day twelve after full recovery. We review the existing literature regarding the epidemiology, pathophysiology, clinical presentation, diagnosis, and treatment of ischemic hepatitis, which is associated with high mortality; therefore early recognition and treatment of the underlying cause are paramount.
- 1 June 2018
- Published by Elsevier in Gastroenterology Clinics of North America
- Vol. 47 (2) , 313-326
Modern Management of Acute Liver Failure
- 1 June 2018
- Published by Elsevier in Gastroenterology Clinics of North America
- Vol. 47 (2) , 313-326
Modern Management of Acute Liver Failure